Myasthenia Gravis clinical trials at UCLA
2 in progress, 1 open to eligible people
Showing trials for
ALXN1720 in Adults With Generalized Myasthenia Gravis
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Los Angeles, California and other locations
Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
Sorry, in progress, not accepting new patients
The purpose of the study is to evaluate the safety and tolerability of switching from intravenous (IV) complement component 5 (C5) inhibitors to subcutaneous (SC) Zilucoplan in study participants with generalized myasthenia gravis (gMG)
Los Angeles, California and other locations
Last updated: